MX2015012812A - Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor. - Google Patents

Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor.

Info

Publication number
MX2015012812A
MX2015012812A MX2015012812A MX2015012812A MX2015012812A MX 2015012812 A MX2015012812 A MX 2015012812A MX 2015012812 A MX2015012812 A MX 2015012812A MX 2015012812 A MX2015012812 A MX 2015012812A MX 2015012812 A MX2015012812 A MX 2015012812A
Authority
MX
Mexico
Prior art keywords
antibody composition
composition enriched
predominant
antibody
novel medicaments
Prior art date
Application number
MX2015012812A
Other languages
English (en)
Spanish (es)
Inventor
Guillaume Chevreux
Nicolas Bihoreau
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of MX2015012812A publication Critical patent/MX2015012812A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2015012812A 2013-03-15 2014-03-14 Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor. MX2015012812A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1352360A FR3003171B1 (fr) 2013-03-15 2013-03-15 Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
PCT/EP2014/055179 WO2014140322A1 (fr) 2013-03-15 2014-03-14 Nouveaux médicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Publications (1)

Publication Number Publication Date
MX2015012812A true MX2015012812A (es) 2016-05-09

Family

ID=48771615

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012812A MX2015012812A (es) 2013-03-15 2014-03-14 Medicamentos novedosos que comprenden una composicion de anticuerpo enriquecida con isoforma de carga mayor.

Country Status (11)

Country Link
US (1) US20160046722A1 (cg-RX-API-DMAC7.html)
EP (1) EP2968533A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016512216A (cg-RX-API-DMAC7.html)
KR (1) KR20150132522A (cg-RX-API-DMAC7.html)
CN (1) CN105163758B (cg-RX-API-DMAC7.html)
AU (1) AU2014230134A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015023209A8 (cg-RX-API-DMAC7.html)
CA (1) CA2907358A1 (cg-RX-API-DMAC7.html)
FR (1) FR3003171B1 (cg-RX-API-DMAC7.html)
MX (1) MX2015012812A (cg-RX-API-DMAC7.html)
WO (1) WO2014140322A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013004841A1 (en) * 2011-07-06 2013-01-10 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
JP6934016B2 (ja) 2016-05-04 2021-09-08 デラヴァル ホルディング アーベー 乳頭カップのためのカートリッジ及び乳頭カップ
FR3053688B1 (fr) * 2016-07-06 2026-05-01 Lab Francais Du Fractionnement Mutants fc a activite fonctionnelle amelioree
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
CN113614107A (zh) 2019-01-23 2021-11-05 Encefa公司 Cd31竞争剂及其用途
JP2022533245A (ja) * 2019-05-23 2022-07-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗体のドメイン特異的電荷変異体の特徴付け
CN114829407B (zh) * 2019-09-23 2024-06-21 南开大学 利用哺乳动物展示筛选FcγR特异性结合Fc
PL4401842T3 (pl) 2021-09-16 2025-11-24 Aboleris Pharma Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania
CN114236010A (zh) * 2021-12-18 2022-03-25 苏州莱奥生物技术有限公司 一种生物活性药物的药代动力学分析方法
CN115073548A (zh) * 2022-08-01 2022-09-20 上海蓝析生物技术有限公司 一种用于重组蛋白药物电荷异构体制备的缓冲体系

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0104865A3 (en) * 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2844513B1 (fr) * 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
CA2832136C (en) * 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
KR100944575B1 (ko) * 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
US7355008B2 (en) * 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
FR2861078B1 (fr) * 2003-10-16 2007-09-21 Lab Francais Du Fractionnement NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE
EP2551282A3 (en) * 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
WO2013004841A1 (en) * 2011-07-06 2013-01-10 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains

Also Published As

Publication number Publication date
JP2016512216A (ja) 2016-04-25
WO2014140322A1 (fr) 2014-09-18
CA2907358A1 (fr) 2014-09-18
US20160046722A1 (en) 2016-02-18
BR112015023209A8 (pt) 2018-01-23
BR112015023209A2 (pt) 2017-07-18
EP2968533A1 (fr) 2016-01-20
AU2014230134A1 (en) 2015-10-29
CN105163758B (zh) 2017-11-17
CN105163758A (zh) 2015-12-16
FR3003171A1 (fr) 2014-09-19
KR20150132522A (ko) 2015-11-25
FR3003171B1 (fr) 2015-04-10

Similar Documents

Publication Publication Date Title
AR118560A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
BR112015030595A2 (pt) moduladores de receptor de estrogênio de azetidina e usos dos mesmos
MX2020009260A (es) Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenerativos.
EA201690159A1 (ru) Способы и композиции для лечения рака
PH12016500094A1 (en) Autotaxin inhibitors
PH12014502406B1 (en) Anti-il-23p19 antibodies
EA201491819A1 (ru) Фармацевтические композиции для комбинированного лечения
MY195289A (en) Anti IL-36R Antibodies
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
EA201490644A1 (ru) Терапевтические пептиды
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
MX2013011922A (es) Compuestos de benceno substituido.
EP4414376A3 (en) Novel depsipeptide and uses thereof
BR112015023209A2 (pt) novos medicamentos compreendendo uma composição de anticorpo enrriquecida com uma carga principal de isoforma
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
WO2014197871A3 (en) Antibody-drug conjugates, compositions and methods of use
HK1213552A1 (zh) 经取代的苯化合物
BR112014010406A2 (pt) cromatografia de sobrecarga e eluto
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
MX371187B (es) Péptidos terapéuticos.
EA201501123A1 (ru) Новые (циано-диметил-метил)-изоксазолы и -[1,3,4]тиадиазолы
AU2018279184A1 (en) Anti-TrkB antibodies